
浏览全部资源
扫码关注微信
1.610083 成都,成都军区总医院: 消化内科
2.610083 成都,成都军区总医院: 检验科
[ 吴晓玲,E-mail:wxllady@163.com WU Xiaoling, E-mail:wxllady@163.com
收稿:2017-03-14,
修回:2017-05-20,
纸质出版:2017-09-30
移动端阅览
牟东, 周德江, 江忠勇, 等. 非酒精性脂肪性肝病患者肝组织水通道蛋白表达差异与多烯磷脂酰胆碱疗效相关性分析[J]. 第三军医大学学报, 2017,39(18):1859-1864.
Dong MU, Dejiang ZHOU, Zhongyong JIANG, et al. Expression difference of liver aquaporins and its correlation with curative effect of multi-phosphatidycholine in nonalcoholic fatty liver disease patients[J]. Journal of Third Military Medical University, 2017, 39(18): 1859-1864.
牟东, 周德江, 江忠勇, 等. 非酒精性脂肪性肝病患者肝组织水通道蛋白表达差异与多烯磷脂酰胆碱疗效相关性分析[J]. 第三军医大学学报, 2017,39(18):1859-1864. DOI: 10.16016/j.1000-5404.201703085.
Dong MU, Dejiang ZHOU, Zhongyong JIANG, et al. Expression difference of liver aquaporins and its correlation with curative effect of multi-phosphatidycholine in nonalcoholic fatty liver disease patients[J]. Journal of Third Military Medical University, 2017, 39(18): 1859-1864. DOI: 10.16016/j.1000-5404.201703085.
目的
2
分析非酒精性脂肪性肝病(nonalcoholic fatty liver disease
NAFLD)患者肝组织水通道蛋白(aquaporin,AQPs)3、7、9表达水平对多烯磷脂酰胆碱(plyene posphatidyl coline
PPC)疗效的影响。
方法
2
分析2014-2016年本院收治的NAFLD患者87例,按病程分组:肝硬化组(
n
=30)
肝纤维化组(
n
=24),肝炎组(
n
=33);超声疗效评估分组:有效组和无效组。随访不同病程的NAFLD患者PPC治疗前后的肝功能酶变化,按照PPC疗效进行分组,比较患者肝组织AQP3、7、9蛋白的表达差异
并进一步分析PPC疗效与AQPs表达水平的相关性。
结果
2
PPC对NAFLD患者治疗整体有效率35.63%,PPC对NAFLD疗效与病程严重程度无关,但与超声的评分密切相关
表现为按照超声评分有效和无效分组的不同病程组患者的谷丙转氨酶(ALT)在PPC治疗后
在每种病程患者中差异有统计学意义
且ALT在PPC治疗后,其变化程度与超声的变化程度呈正相关,肝硬化组(
R
=0.780,
P
<
0.01),肝纤维化组(
R
=0.879,
P
<
0.01),肝炎组最高(
R
=0.900,
P
<
0.01)。PPC治疗NAFLD效果与患者初始的肝组织AQPs的表达存在相关性:NAFLD患者肝组织AQP7、9表达量与肝功能酶的变化量呈正相关(AQP9:
R
=0.972
AQP7:
R
=0.537),而AQP3的表达水平与肝功能酶的变化量呈负相关(
R
=-0.881); AQP7、9表达量与超声评分的变化量呈正相关(AQP9:
R
=0.763
AQP7:
R
=0.311),而AQP3的表达水平与肝功能酶的变化量呈负相关(
R
-0.795)。
结论
2
多烯磷脂酰胆碱对非酒精性脂肪性肝病的疗效与水通道蛋白表达差异密切相关,提示AQPs表达水平可能影响PPC疗效。
Objective
2
To determine the effect of expression levels of aquaporins (AQPs) 3
7 and 9 on the therapeutic effect of multi-phosphatidycholine (PPC) in the patients with nonalcoholic fatty liver disease (NAFLD).
Methods
2
A total of 87 NAFLD patients admitted in our hospital from 2014 to 2016 were recruited in this study. According to their courses of the disease
they were divided into cirrhosi (
n
=30)
liver fibrosis (
n
=24)
and hepatitis groups (
n
=33). After the treatment with PPC
ultrasonic examination was used to evaluate the effective and ineffective patients
and the changes of liver function enzymes were also observed. The expression levels of AQPs
3
7 and 9 in the liver tissues were compared in the patients with different courses of NAFLD. The correlation between the effect of PPC and the expression levels of AQPs were analyzed.
Results
2
The total effective rate of PPC was 35.63% in the NAFLD patients
and the effect of PPC on NAFLD was not related to the severity of the disease
but was closely related to the scores of ultrasound examination. Significant differences were found in ALT level between the PPC effective and ineffective patients
and among the patients with difference courses of NAFLD. What's more
the ALT level was positively correlated with changes of ultrasound examination in the cirrhosi group (
R
=0.780
P
<
0.01)
liver fibrosis group (
R
=0.879
P
<
0.01)
and the hepatitis group (
R
=0.900
P
<
0.01). The effect of PPC on NAFLD was correlated with the initial expression levels of AQPs in the liver tissues. The levels of AQPs 7 and 9 were positively correlated with the changes of liver function (AQP9:
R
= 0.972
AQP7:
R
=0.537)
and that of AQP 3 was negatively correlated with the changes of liver function enzymes (
R
=-0.881); The expression levels of AQPs 7 and 9 were positively correlated with the change of ultrasonic score (AQP9:
R
=0.763
AQP7:
R
=0.311)
and that of AQP 3 was negatively correlated with the change of liver function (
R
=-0.795).
Conclusion
2
The effect of PPC on NAFLD is closely related to the expression levels of AQPs
suggesting that the levels may influence the effect of PPC.
PARK S H, JEON W K, KIM S H, et al. Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults[J]. J Gastroenterol Hepatol, 2006, 21(1 Pt 1): 138-143. DOI: 10.1111/j.1440-1746.2005.04086.x.
FAN J G, FARRELL G C. Epidemiology of non-alcoholic fatty liver disease in China[J]. J Hepatol, 2009, 50(1): 204-10. DOI: 10.1016/j.jhep.2008.10.010
MELO R, FIELDHOUSE R, MELO A, et al. A Machine Learning Approach for Hot-Spot Detection at Protein-Protein Interfaces[J]. Int J Mol Sci, 2016, 17(8): DOI: 10.3390/ijms17081215
TARDELLI M, MORENO-VIEDMA V, ZEYDA M, et al. Adiponectin regulates aquaglyceroporin expression in hepatic stellate cells altering their functional state[J]. J Gastroenterol Hepatol, 2017 J, 32(1): 253-260. DOI: 10.1111/jgh.13415.
GU L Y, QIU L W, CHEN X F, et al. Oleic acid-induced hepatic steatosis is coupled with downregulation of aquaporin 3 and upregulation of aquaporin 9 via activation of p38 signaling[J]. Hormon-und Stoffwechselforschung = Hormones et metabolisme, 2015, 47(4): 259-264. DOI: 10.1055/s-0034-1384569.
CAI C, WANG C, JI W, et al. Knockdown of hepatic aquaglyceroporin-9 alleviates high fat diet-induced non-alcoholic fatty liver disease in rats[J]. Int Immunopharmacol, 2013, 15(3): 550-556. DOI: 10.1016/j.intimp.2013.01.020.
GUO X, SUN T, YANG M, et al. Prognostic value of combined aquaporin 3 and aquaporin 5 overexpression in hepatocellular carcinoma[J]. Biomed Res Int, 2013, 2013: 206525. DOI: 10. 1155/2013/206525.
钱蕴秋.超声诊断学[M].第2版.西安:第四军医大学出版社, 2008: 532.
QIAN Y Q. Diagnostic Medical Sonography. The second edition[M]. Xi'an: The Fourth Military Medical University Press. 2008: 532.
苏红领, 朱玉侠, 高正军, 等.双环醇与多烯磷脂酰胆碱治疗非酒精性脂肪肝的疗效比较[J].中华肝脏病杂志, 2011, 19(7): 552-553. DOI: 10.3760/cma.j.issn.1007-3418.2011.07. 019.
SU H L, ZHU Y X, GAO Z J, et al. Efficacy comparison between bicyclol and polyene phosphatidylcholine treatments for the patients with nonalcoholic fatty liver disease[J]. Chin J Hepatol, 2011, 19(7): 552-553. DOI: 10.3760/cma.j.issn.1007-3418.2011.07.019.
李进, 李月翠, 胡伟跃, 等.自拟降脂护肝方联合多烯磷脂酰胆碱治疗非酒精性脂肪肝的临床研究[J].中华中医药学刊, 2015, 33(1): 236-239. DOI: 10.13193/j.issn.1673-7717. 2015.01.071.
LI J, LI Y C, HU W Y, et al. Clinical Research of Self-Prepared Decoction of Lipid-Decreasing and Liver Protection Combined Polyene Phosphatidylcholine for Treatment of Nonalcoholic Fatty Liver Disease[J]. Chin Arch Tradi Chin Med, 2015, 33(1): 236-239. DOI: 10.13193/j.issn.1673-7717.2015.01.071.
刘梅, 陆伦根, 曾民德.多烯磷脂酰胆碱对肝细胞保护机制的研究进展[J].肝脏, 2006, 11(1): 43-45. DOI: 10.3969/j.issn.1008-1704.2006.01.016.
LIU M, LU L G, ZENG M D. Advances in the hepatocellulor protective machanisms of polyenylphosphatidylcholine[J]. Chin Hepatol, 2006, 11(1): 43-45. 1111111155555555j.issn.1008-1704.2006.01.016.
KOYAMA Y, YAMAMOTO T, TANI T, et al. Expression and localization of aquaporins in rat gastrointestinal tract[J]. Am J Physiol, 1999, 276(3 Pt 1): C621-C627.
ASHRAF Z, ALAMGEER, RASOOL R, et al. Synthesis, Bioevaluation and Molecular Dynamic Simulation Studies of Dexibuprofen-Antioxidant Mutual Prodrugs[J]. Int J Mol Sci, 2016, 17(12). pii: E2151. DOI: 10.3390/ijms17122151.
LAFORENZA U. Water channel proteins in the gastrointestinal tract[J]. Mol Aspects Med, 2012, 33(5-6): 642-650. DOI:10.1016/j.mam.2012.03.001.
GREGOIRE F, LUCIDI V, ZERRAD-SAADI A, et al. Analysis of aquaporin expression in liver with a focus on hepatocytes[J]. Histochem Cell Biol, 2015, 144(4): 347-363. DOI: 10.1007/s00418-015-1341-3.
0
浏览量
0
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621